Literature DB >> 27033077

Assessing PTEN Subcellular Localization.

Anabel Gil1,2, José I López3,4, Rafael Pulido5,6,7.   

Abstract

PTEN subcellular localization is fundamental in the execution of the distinct PTEN biological activities, including not only its PI(3,4,5)P3 phosphatase activity when associated to membranes but also its subcellular compartment-specific interactions with regulatory and effector proteins, including those exerted in the nucleus. As a consequence, PTEN subcellular localization is tightly regulated in vivo by both intrinsic and extrinsic mechanisms. The plasma membrane/nucleus/cytoplasm partitioning of PTEN has been the focus of several studies, both from a mechanistic and from a disease-association point of view. Here, we summarize the current knowledge on PTEN plasma membrane/nucleus/cytoplasm distribution, and present subcellular fractionation, immunofluorescence, and immunohistochemical methods to study the distribution and shuttling of PTEN between these subcellular compartments.

Entities:  

Keywords:  Immunofluorescence; Immunohistochemistry; PTEN; Subcellular fractionation; Tumor suppression

Mesh:

Substances:

Year:  2016        PMID: 27033077     DOI: 10.1007/978-1-4939-3299-3_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  A pathogenic role for germline PTEN variants which accumulate into the nucleus.

Authors:  Janire Mingo; Isabel Rodríguez-Escudero; Sandra Luna; Teresa Fernández-Acero; Laura Amo; Amy R Jonasson; Roberto T Zori; José I López; María Molina; Víctor J Cid; Rafael Pulido
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

2.  Immunofluorescence Detection of Plasma Membranous PTEN in Cultured Cells.

Authors:  Takashi Kato
Journal:  J Histochem Cytochem       Date:  2022-02-24       Impact factor: 2.479

3.  Overexpressing TPTE2 (TPIP), a homolog of the human tumor suppressor gene PTEN, rescues the abnormal phenotype of the PTEN-/- mutant.

Authors:  Daniel F Lusche; Emma C Buchele; Kanoe B Russell; Benjamin A Soll; Michele I Vitolo; Michael R Klemme; Deborah J Wessels; David R Soll
Journal:  Oncotarget       Date:  2018-04-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.